Here you can find the latest TOPADUR news & events.
TOPADUR PHARMA AG has been awarded an Innosuisse grant to fund our collaborative project with Yonsei University and Juviv Inc.
We are proud to be recognized as one of Switzerland's most promising scale-ups in 2023.
TOPADUR announced that Pascal Brenneisen has been appointed CEO, effective April 1, 2023, on top of his Board member assignment.
Topical Wound Treatment with a NO-Releasing PDE5 Inhibitor Formulation Enhances Blood Perfusion and Promotes Healing in Mice.
We are proud to be recognized as one of Switzerland's most promising scale-ups in 2022.
A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Activates Autophagy in Primary Skin Fibroblasts.
Do you need more information or references? Media contact